Replagal for Fabry disease in children and adults in India
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial studies Replagal (enzyme replacement therapy) for people with Fabry disease who have not used it before. It aims to see how the treatment works and how safely it can be used in children and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have a confirmed diagnosis of Fabry disease by a gene change and/or low alpha-galactosidase A level
- You have Fabry symptoms, as decided by the study doctor
- You have never received Replagal before
- You can sign consent (or a parent/guardian can) and follow all study visits and procedures
- If you can become pregnant: you have a negative pregnancy test and use two approved birth-control methods during the study
- If you are a sexually active non-sterilized male: you agree to use condoms during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if enzyme replacement therapy works well and is safe for Fabry disease. It is for people who are already prescribed this treatment.
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
This trial tests if the oral drug migalastat is safe and works for children aged 2 to under 12 with a specific type of Fabry disease. It may be an option if your child has not been on enzyme therapy recently and has a compatible gene variant.
This study tests an enzyme replacement therapy (agalsidase alfa) for Fabry disease in Chinese children and adults. It's an observational study that follows patients who receive the treatment as part of their regular care.
This study is for people with Fabry disease who are taking or planning to take the medication Elfabrio (pegunigalsidase alfa). It will look at how safe and effective the treatment is in real-world use.
This study checks whether certain heart-related blood tests and heart scans can help monitor people with Fabry disease. It may be useful for both people who have never received enzyme replacement therapy and those who have.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.